Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
Golden Age Health and Innostellar team up on a 10-year pact to bring sight-saving LX-101 gene therapy to China, aiming to help RPE65 IRD patients 'see the future, clearly.'
'Partnering with Innostellar positions GAH at the forefront of gene therapy in China's rapidly expanding ophthalmology market,' said Francis Wan, Chief Executive Officer of Golden Age Health. 'Our integrated approach aims to deliver sight-saving innovation to patients swiftly and comprehensively.'
Dr Wang Fenghua, Founder & CEO of Innostellar, added: 'By joining forces with GAH, we can ensure LX-101 reaches patients across China rapidly and—crucially—at prices families can afford, thanks to efficiencies gained through local development and manufacturing. Improving patient access lies at the heart of our mission.
About Inherited Retinal Dystrophies
Inherited retinal dystrophies (IRDs)—including retinitis pigmentosa (RP) —are genetic disorders that progressively destroy photoreceptors, leading to severe vision impairment or blindness, often from childhood. RP affects approximately 1 in 3,000–4,000 people worldwide and is officially listed in China's National Rare Disease Catalog (first list, 2018), underscoring the country's commitment to improving outcomes for affected patients.
About LX-101
LX-101 is an adeno-associated-virus (AAV) gene therapy delivering a functional RPE65 gene directly to retinal cells, aiming to restore the visual cycle in patients with biallelic RPE65-mutation IRDs. The programme is in Phase III clinical development in China, with top-line results expected in Q4 2025 and initiate NMPA New Drug Application soon after. If approved, LX-101 would provide eligible patients with a single-dose, durable treatment designed to halt—or potentially reverse—vision loss.
About Golden Age Health
Golden Age Health is a specialty pharmaceutical company dedicated to redefining patient access to medicine across China, Asia-Pacific and beyond. Headquartered in Singapore, GAH pairs data-driven market-access expertise with deep medical-affairs and RWE capabilities to bring high-impact therapies to underserved populations.
About Innostellar Biotherapeutics
Innostellar Biotherapeutics is a Shanghai-based biotechnology firm advancing innovative gene-therapy medicines for ocular and other genetic diseases and chronic diseases. Its pipeline is led by LX-101, the first gene therapy of its kind to enter late-stage development in China.
Forward-Looking Statements
This release contains forward-looking statements, including expectations regarding clinical development, regulatory approvals and commercial launches. These statements involve risks and uncertainties that may cause actual outcomes to differ materially.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
19 hours ago
- Hamilton Spectator
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering will not be subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering as more specifically described in the Offering Document and for gout programs, general corporate and working capital purposes. In connection with the Offering, the Company paid an aggregate of $12,264 in finder's fees and issued, in aggregate, 16,800 finder's warrants. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The issuance of 8,191 Units to an insider of the Company constitutes a 'related party transaction' as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ('MI 61-101'). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company relied on exemptions from the formal valuation and minority shareholder approval requirements, respectively, as neither the fair market value of the Units nor the consideration for such Units, insofar as it involves the insider, exceeds 25 percent of the Company's market capitalization. In other news, the non-brokered private placement that was announced on May 19, 2025 will not proceed. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at . For more information, please contact: Forward-Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on . Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Business Wire
2 days ago
- Business Wire
NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners. NFL Biosciences obtained a €600,000 'Innovation Advance' repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate. This €1.2 million adds to the €3.0 million raised in the oversubscribed capital increase at the end of May 2025. The company also expects to secure additional non-dilutive funding and plans to benefit each year from the reimbursement of a portion of its R&D expenses through the Research Tax Credit. These funds are allocated to the continued development of NFL-101, its proprietary drug indicated for smoking cessation. The company is currently engaged in scientific advice procedures with European regulatory authorities and the FDA. The feedback expected at the end of the summer will enable the company to confirm its development strategy, notably in relation to manufacturing, preclinical and clinical aspects. 'We would like to sincerely thank Bpifrance for its support, as well as our banking partners Société Générale and Banque Populaire du Sud. We have recently secured €4.2 million to support our development, and we are confidently approaching the launch of Phase 3. We are also continuing to seek additional non-dilutive funding and remain focused on rigorously managing our structural costs,' commented Bruno Lafont, Chief Executive Officer of NFL Biosciences. About NFL Biosciences: NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an 'Innovative Company' eligible for FCPI investment. More information on
Business Upturn
2 days ago
- Business Upturn
Q-Gold Resources engages FHB Consulting Services LLC to update the Resource Estimate for Quartz Mountain
By GlobeNewswire Published on July 21, 2025, 16:30 IST TORONTO, July 21, 2025 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (TSXV: QGR) ('Q-Gold' or the 'Company') is pleased to announce that it has retained FHB Consulting Services LLC ('FSB Consulting'), a Washington-based geological consulting firm that is independent from the Company, to conduct an updated review and revision of the historical estimate that has not been confirmed by Q-Gold at the later stage mineral exploration project located in south-central Oregon (the 'Quartz Mountain Project') that the Company intends to acquire pursuant to a share exchange agreement dated March 31, 2025 (the 'Acquisition'). For more information about the Acquisition, please see the Company's press release dated April 3, 2025, a copy of which is available under the Company's SEDAR+ profile at This initiative is expected to entail a comprehensive revision of the previous mineral resource estimates, originally completed by M. Lechner in 2012 and later updated in-house by the vendor of the Quartz Mountain Project, Alamos Gold Inc. ('Alamos'), in 2016, prepared by Marc Jutras, Ginto Consulting Inc. As part of the review process, the Company anticipates that FHB Consulting will conduct a field visit to the project site in Oregon. The Company expects that the updated resource estimate will incorporate data from boreholes drilled at Crone Hill and Quartz Butte by Alamos in 2015, as well as historical drilling data from earlier exploration campaigns. The current resource estimate for the Quartz Mountain Project is presented in Table 1. Table 1: Mineral Resources at Quartz Mountain as reported in Alamos' Mineral Reserves and Mineral Resources as at December 31, 2024. Gold Mineral Resources Tonnes (000) Grade (g/t Au) oz Au (000) Measured and Indicated Mineral Resources 12,156 0.87 339 Inferred Resources 39,205 0.91 1.147 Notes to Mineral Reserve and Resource Tables: Alamos' Mineral Reserves and Mineral Resources as at December 31, 2024 are classified in accordance with the Canadian Institute of Mining Metallurgy and Petroleum's 'CIM Standards on Mineral Resources and Reserves, Definition and Guidelines' as per Canadian Securities Administrator's NI 43-101 requirements. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. Mineral Resources are exclusive of Mineral Reserves. All Measured, Indicated and Inferred open pit Mineral Resources are pit constrained. The resource is based on a gold price of $1400/oz, with cut-off grades of 0.21 g/t Oxide and 0.6 g/t Sulphide and 65-80% metallurgical recovery. Mineral resources for the Quartz Mountain Project are available on the Alamos' website: Alamos Gold – Quartz Mountain Project United States ( Q-Gold anticipates that this updated assessment will provide a more accurate and current understanding of the mineral resource potential across what the Company believes to be the key target at the Quartz Mountain Project. Q-Gold remains committed to closing the Acquisition and unlocking the potential of what the Company believes to be a sizeable deposit, leveraging modern exploration techniques to build shareholder value. Dr. Andreas Rompel, VP Exploration and Chief Operating Officer of Q-Gold, stated: 'We are very pleased to have engaged such a renowned company to review and update the resource for this gold deposit, which we believe holds significant upside potential within Quartz Mountain and the neighbouring Angle's Camp — areas we intend to explore further in the near future.' About the Existing Quartz Mountain Property The Quartz Mountain Project is an advanced-stage exploration project located in south-central Oregon. Over the years, approximately 100,000 metres of drilling has been conducted, with the majority of work focused on the Crone Hill and Quartz Butte deposits, which host a measured, indicated and inferred mineral resource. Combined with the Angel's Camp property (which, for certainty, comprises a portion of the Quartz Mountain Project), the project covers a large land package which the Company believes offers significant exploration potential (for more information about the Quartz Mountain Project, please see the Company's press release dated April 3, 2025). Qualified Persons The scientific and technical information contained in this press release has been reviewed and approved by Jason Arnold, an independent consultant who is a 'Qualified Person' as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects ('NI-43-101') . About Q-Gold Resources Ltd. Q-Gold Resources (TSXV: QGR, OTC: QGLDF) is a publicly traded Canadian-based mineral exploration company targeting high-grade gold and silver discoveries in multiple jurisdictions. Q-Gold is currently exploring for gold at the past-producing Foley Gold Mine in Mine Centre, Ontario. For further information, contact:Dr. Andreas RompelChief Operating Officer and VP Exploration [email protected] Cell: +1 778 987 9114 Cautionary Notes The content and grades of any mineral deposits at the Company's properties are conceptual in nature. There has been insufficient exploration to define a mineral resource on its properties and it is uncertain if further exploration will result in any target being delineated as a mineral resource. This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Company's ability to complete the Acquisition (including the requisite concurrent financing) and to explore and develop the Quartz Mountain Project, the Company's expectations of FSB Consulting for its review and update of the current mineral resource at the Quartz Mountain Project, and the Company's beliefs, plans, expectations or intentions for the Quartz Mountain Project, and other matters related thereto. Generally, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved'. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: receipt of necessary approvals; successful completion of a financing and the satisfaction of the other closing conditions necessary to complete the Acquisition; general business, economic, competitive, political and social uncertainties; future mineral prices and market demand; accidents, labour disputes and shortages and other risks of the mining industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
